Indications
Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
Composition
- Active substance
- lurbinectedin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zepzelca
- Active substance
- lurbinectedin
- ATC code
- L01XX69
- Therapeutic area
- Small Cell Lung Carcinoma
- Marketing authorisation holder
- Pharma Mar S.A.